Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Teneliximab

🥰Excellent
Catalog No. T76830Cas No. 299423-37-3
Alias Chi220, BMS 224819, Anti-Human CD40 Recombinant Antibody

Teneliximab (BMS 224819) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interactions.Teneliximab exerts its partial agonist activity through CD40 and peripheral B-cell depletion, and may be used to study organ transplant rejection and rheumatoid arthritis.

Teneliximab

Teneliximab

🥰Excellent
Purity: 99.19% (SEC-HPLC)
Catalog No. T76830Alias Chi220, BMS 224819, Anti-Human CD40 Recombinant AntibodyCas No. 299423-37-3
Teneliximab (BMS 224819) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interactions.Teneliximab exerts its partial agonist activity through CD40 and peripheral B-cell depletion, and may be used to study organ transplant rejection and rheumatoid arthritis.
Pack SizePriceAvailabilityQuantity
1 mg$163In Stock
5 mg$428In Stock
10 mg$662In Stock
25 mg$987In Stock
50 mg$1,370In Stock
100 mg$1,850In Stock
200 mg$2,490In Stock
Bulk & Custom
Add to Cart
Questions
View More
Select Batch
Concentration:4.08 mg/mL
Purity:99.19% (SEC-HPLC)
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Teneliximab (BMS 224819) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interactions.Teneliximab exerts its partial agonist activity through CD40 and peripheral B-cell depletion, and may be used to study organ transplant rejection and rheumatoid arthritis.
In vitro
METHODS: Monocytes were freshly prepared from human blood samples. Cells were cultured with anti-IgM immunoglobulin (5 μg/ml) and Teneliximab (BMS 224819) (5 μg/ml). The effect on cell proliferation was further evaluated.
RESULTS Teneliximab (BMS 224819) promoted the proliferation of stimulated B cells. [1]
In vivo
METHODS: Crab monkey groups were immunized with SRBC and received a single intravenous dose of Teneliximab (BMS 224819) at 10, 40, or 100 mg/kg to observe the ability of Teneliximab (BMS 224819) to inhibit primary Ab responses in vivo.
RESULTS Significant inhibition of the primary humoral immune response to SRBC by Teneliximab (BMS 224819) was observed at all three dose levels. [1]
AliasChi220, BMS 224819, Anti-Human CD40 Recombinant Antibody
Chemical Properties
Molecular Weight146.06 kDa
Cas No.299423-37-3
Storage & Solubility Information
Storagestore at low temperature | store at -80°C | Shipping with blue ice.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Teneliximab | purchase Teneliximab | Teneliximab cost | order Teneliximab | Teneliximab in vivo | Teneliximab in vitro | Teneliximab molecular weight